An observational study in BCC - Basal Cell Carcinoma, BCC and Skin Diseases, sponsored by Vejle Hospital. Completed at 1 site in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-26.
Sponsored by Vejle Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Carcinoma, Basal Cell with a site in Denmark — 2 open to participants now, 4 under way, none of them phase 3. Carcinoma, Basal Cell · Denmark.
Among the 21 studies in Carcinoma, Basal Cell with a site in Denmark, this one is the only one that started in 2024, is one of 4 observational ones, and was the 18th registered.
389 studies on the registry are indexed under Carcinoma, Basal Cell; 69 are open to participants now.
Browse Carcinoma, Basal Cell studies →2 of the 21 studies in Carcinoma, Basal Cell with a site in Denmark are open now. Recruiting first, the newest first:
Bispebjerg Hospital · Sites in Denmark
Ages 18+
University of Aarhus · Sites in Denmark
Ages 18+
A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →
Of the 52 Carcinoma, Basal Cell studies recruiting now, 48 (92%) set no upper age limit and none (0%) stop at 75 or younger; 9 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 7 · Phase 3 5
First in 2003; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 210 is above the median of 142 across 95 observational studies indexed under Carcinoma, Basal Cell.
Median enrollment 44 across the 16 interventional studies, 130 across the 4 observational. Of the 13 that completed or were terminated, 5 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 21 have an industry lead sponsor. The 10 most frequent:
Vejle Hospital is the lead sponsor of 95 studies on the registry; 13 are open to participants now.
Vejle Hospital has 1 study filed under Carcinoma, Basal Cell — fewer than ten, so there is no comparison to draw.
1 of the studies in Carcinoma, Basal Cell with a site in Denmark that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07803406Bispebjerg HospitalMultimodal Imaging of Basal Cell Carcinoma: A Usability Study | 2027-06-25 |
Add it to your calendar (.ics) → With an account.
Among the 21 studies in Carcinoma, Basal Cell with a site in Denmark, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose is to investigate the diagnostic value (sensitivity and specificity) of dermal-Optical Coherence Tomography (D-OCT, VivoSight Dx), in patients with clinically suspected BCC lesions inside the periocular region and compare these results to previous reports using D-OCT in diagnosing lesions outside the periocular area.
The Hypotheses:
Consecutive enrolment of newly referred patients under the diagnosis "clinically suspected BCC" in the periocular area
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Diagnostic accuracy of D-OCT in diagnosing BCC inside the periocular region, compared to previous reports on lesions outside the periocular region
To assess if the sensitivity and specificity of D-OCT in diagnosing BCC inside the periocular region is comparable to previous reports on BCC lesions outside the periocular region using the standard probe
Time frame: March 2024-August 2026
Comparative diagnostic accuracy of D-OCT´s standard vs customized probe for diagnosing BCC
To compare the sensitivity and specificity of each D-OCT probe for diagnosing periocular BCC, with reference to punch biopsy results.
Time frame: March 2024-August 2026
Comparative diagnostic accuracy of D-OCT´s standard vs customized probe for subtyping BCC
To compare the sensitivity and specificity of each D-OCT probe for subtyping periocular BCC, with reference to punch biopsy results.
Time frame: March 2024-August 2026
Observer agreement in identifying presence/absence of BCC lesions, using D-OCT
This measure, assesses the consistency among observers in identifying the presence or absence of BCC lesions through the utilization of D-OCT imaging.
Time frame: March 2024-August 2026
Observer agreement in classifying BCC lesions into subtypes, using D-OCT
This measure, evaluates the level of agreement among observers in categorizing BCC lesions into specific subtypes based on D-OCT imaging. Potential diagnostic features from lesion types will be tested.
Time frame: March 2024-August 2026
Observer agreement in mapping BCC lesions prior to surgery, using D-OCT
This measure, examines the agreement among observers in accurately mapping the extension of BCC lesions prior to surgery with the assistance of D-OCT imaging.
Time frame: March 2024-August 2026
Quantification of learning curve in correctly diagnosing BCC over time with increasing experience with D-OCT
This measure, quantifies the improvement in skills over time among observers in diagnosing BCC lesions using D-OCT imaging. It aims to determine the rate at which observers become adept at interpreting D-OCT images for BCC diagnosis.
Time frame: March 2024-August 2026
Quantification of learning curve in correctly identifying BCC subtypes over time with increasing experience with D-OCT
This measure, quantifies the improvement in skills over time among observers in accurately identifying different subtypes of BCC lesions using D-OCT imaging. It aims to determine the rate at which observers become adept at interpreting D-OCT images for BCC subtyping.
Time frame: March 2024-August 2026
Quantification of skills in correctly demarcating BCC over time with increasing experience with D-OCT
This measure, quantifies the improvement in skills over time among observers in precisely delineating the borders of BCC lesions prior to surgery using D-OCT imaging. It assesses the improvement in demarcation accuracy with increasing experience.
Time frame: March 2024-August 2026
Accuracy of D-OCT in delineation of periocular BCC extension prior to surgery
Evaluation af sensitivity of D-OCT imaging in delineation (mapping) of periocular BCC tumour extension - comparing findings with visible boundaries and histopathological diagnosis (considered the gold standard)
Time frame: March 2024-August 2026
Ran from Apr 2024 to primary completion in Mar 2026, 23 months.
Of 40 observational studies under Carcinoma, Basal Cell, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 75. This study's 23 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Vejle Hospital